fingolimod 0.25 MG Disintegrating Oral Tablet
- RxCUI
- 2610295
- RxNorm name
- fingolimod 0.25 MG Disintegrating Oral Tablet
- Display name
- fingolimod 0.25 MG Disintegrating Oral Tablet
- Full name
- fingolimod 0.25 MG Disintegrating Oral Tablet
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:19
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TASCENSO ODT | FINGOLIMOD LAURYL SULFATE | Cycle Pharmaceuticals Ltd | bf8e7f89-ea09-43c7-a7eb-e44724350721 | 2026-01-08 | Warnings, Adverse reactions | 2610295 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| bf8e7f89-ea09-43c7-a7eb-e44724350721 | fingolimod 0.25 MG Disintegrating Oral Tablet | PSN | 8 | These highlights do not include all the information needed to use TASCENSO ODT ® safely and effectively. See full prescribing information for TASCENSO ODT. TASCENSO ODT (fingolimod) orally disintegrating tablets Initial U.S. Approval: 2010 | 20260108 |
| bf8e7f89-ea09-43c7-a7eb-e44724350721 | fingolimod 0.25 MG Disintegrating Oral Tablet | SCD | 8 | These highlights do not include all the information needed to use TASCENSO ODT ® safely and effectively. See full prescribing information for TASCENSO ODT. TASCENSO ODT (fingolimod) orally disintegrating tablets Initial U.S. Approval: 2010 | 20260108 |
| bf8e7f89-ea09-43c7-a7eb-e44724350721 | fingolimod 0.25 MG (as fingolimod lauryl sulfate 0.47 MG) Disintegrating Oral Tablet | SY | 8 | These highlights do not include all the information needed to use TASCENSO ODT ® safely and effectively. See full prescribing information for TASCENSO ODT. TASCENSO ODT (fingolimod) orally disintegrating tablets Initial U.S. Approval: 2010 | 20260108 |